Table 1.
Demographic, clinical and pathological features of patients with IgA nephropathy
| Characteristics | Values |
|---|---|
| Patients numbers | 147 |
| Cytokines–biopsy time intervala (months) | 27.93 (6.17–63.37) |
| Mean age (yr) | 35 (29–45) |
| Male, n (%) | 71 (48.3) |
| Systolic BP (mmHg) | 120 (110–130) |
| Diastolic BP (mmHg) | 75 (70–80) |
| Mean arterial pressure (mmHg) | 90 (83–97) |
| Urinary red blood cell (/μL) | 29 (7–79) |
| Urinary protein to serum creatinine ratio (mg/g Cr) | 595 (244–1305) |
| 24-h urine protein excretion (g/24 h) | 0.82 (0.38–1.55) |
| < 0.3 | 27 (18.4%) |
| 0.3–0.99 | 59 (40.1%) |
| 1.0–2.99 | 46 (31.3%) |
| ≥ 3 | 15 (10.2%) |
| Serum creatinine (mg/dL) | 1.07 (0.84–1.39) |
| Serum IgA (g/L) | 2.22 (1.82–3.22) |
| Cystatin C (mg/dL) | 1.06 (0.93–1.57) |
| eGFR (mL/min•1.73m2)b | 79.29 (60.00–104.29) |
| CKD Stagesc, n (%) | |
| 1 | 57 (38.8) |
| 2 | 49 (33.3) |
| 3a | 22 (15.0) |
| 3b | 8 (5.4) |
| 4 | 5 (3.4) |
| 5 | 6 (4.1) |
| Oxford classificationd, n (%) | |
| M0/ M1 | 16(10.9), 131(89.1) |
| E0/E1 | 113(76.9), 34(23.1) |
| S0/S1 | 24(16.3), 123(83.7) |
| T0/T1/T2 | 45(30.6), 65(44.2), 37(44.2) |
| C0/C1/C2 | 66(44.9), 66(44.9), 15(10.2) |
| Medical treatments, n (%) | |
| Untreated | 35 (23.8) |
| Corticosteroids | 71 (48.3) |
| Immunosuppressants | 76 (51.7) |
| ACE-Is/ARBs | 99 (67.3) |
Data are presented as median (interquartile range) or frequency in percent
BP: blood pressure; 1 mmHg = 0.133Kpa; eGFR: estimated glomerular filtration rate; ACE-Is: angiotensin converting
enzyme inhibitors; ARBs: angiotensin II receptor blockers. M: mesangial hypercellularity score < 0.5 (M0) or > 0.5 (M1);
E: endocapillary hypercellularity absent (E0) or present (E1); S: segmental glomerulosclerosis absent (S0) or present (S1),
presence or absence of podocyte hypertrophy/tip lesions in biopsy specimens with S1; T: tubular atrophy/interstitial
fibrosis < 25% (T0), 26–50% (T1), or > 50% (T2); C: cellular/fibrocellular crescents absent (C0), present in at least 1
glomerulus (C1), in > 25% of glomeruli (C2)
aTime interval between renal biopsy of patients with IgA nephropathy and sample collection
beGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [19]
cCKD stages 1–5 were divided by eGFR≥90 (G1), 60–89 (G2), 45–59 (G3a), 30–44 (G3b), 15–29 (G4), and < 15 (G5) mL/min/1.73 m2, respectively, according to the new KDIGO (Kidney Disease: Improving Global Outcomes) classification [20]
dDetermined in accordance with the Oxford classification [5]